Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Farmers Insurance
Fish and Richardson
US Department of Justice
Teva
McKesson
Boehringer Ingelheim
Queensland Health
Chubb

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,101,576

« Back to Dashboard

Which drugs does patent 7,101,576 protect, and when does it expire?


Patent 7,101,576 protects MEGACE ES and is included in one NDA. There has been one Paragraph IV challenge on Megace ES.

This patent has thirty-three patent family members in nineteen countries.

Summary for Patent: 7,101,576

Title:Nanoparticulate megestrol formulations
Abstract:The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
Inventor(s): Hovey; Douglas (Trooper, PA), Pruitt; John (Collegeville, PA), Ryde; Tuula (Malvern, PA)
Assignee: Elan Pharma International Limited (Dublin, IE)
Application Number:10/412,669
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Endo Pharms IncMEGACE ESmegestrol acetateSUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,101,576

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,088Nanoparticulate megestrol formulations► Subscribe
9,107,827Nanoparticulate megestrol formulations► Subscribe
9,101,549Nanoparticulate megestrol formulations► Subscribe
9,101,540Nanoparticulate megestrol formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,101,576

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria539737► Subscribe
Australia2003230885► Subscribe
Australia2003231071► Subscribe
Australia2006262144► Subscribe
BrazilPI0612665► Subscribe
Canada2481390► Subscribe
Canada2508301► Subscribe
Canada2613466► Subscribe
China101242810► Subscribe
Cyprus1113036► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Fuji
Chinese Patent Office
Federal Trade Commission
US Department of Justice
Chubb
QuintilesIMS
Novartis
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot